Biobanking and secondary use of healthcare data enable considerable improvement to healthcare through personalized medicine including innovative therapies, pharmaceuticals, medical technology, and healthcare processes tailored for the needs of individuals. The data-driven precision medicine ecosystem requires contributions from a large variety of stakeholders as well as public investments to boost ecosystem growth. This paper introduces a system dynamics model describing mechanisms for biobank data and biosample accumulation and the related impact to pharmaceutical R&D projects. The preliminary simulation results reflect the important role of public funding of the infrastructure needed for biobank and register data exploitation as well as setting up services to attract more donors. Large public-private precision medicine projects, such as the FinnGen project are in a key role. Further work is needed to improve the ecosystem model precision especially in taking into account the differences between pharmaceutical R&D projects and their data exploitation needs.
|Publication status||Published - Jul 2020|
|MoE publication type||Not Eligible|
|Event||2020 International Conference of the System Dynamics Society, SDS 20 - Virtually, Bergen, Norway|
Duration: 19 Jul 2020 → 24 Jul 2020
|Conference||2020 International Conference of the System Dynamics Society, SDS 20|
|Period||19/07/20 → 24/07/20|
- system dynamics